30 results about "Angiopoietin-like Protein" patented technology

Compounds comprising an angiopoietin-like protein 6 (Angptl6) peptide for use in the treatment of metabolic syndrome, in particular, obesity and insulin resistance are described.

Modulators of angiopoietin-like 4 protein are provided along with methods for their use in the treatment of diseases and pathological conditions. Combinations of ANGPTL4 antagonists and other therapeutics, e.g., anti-cancer agents, and methods of their use in the treatment of mammals susceptible to or diagnosed with cancer, or with relapse tumor growth or relapse cancer cell growth are also provided.

The present invention provides methods and compositions for treating or preventing atherosclerosis in a subject. The methods of the present invention comprise administering an inhibitor of angiopoietin-like protein-3 (ANGPTL3) to a subject who has atherosclerosis or is at risk of developing atherosclerosis. In certain embodiments, the ANGPTL3 inhibitor is an antibody or antigen-binding fragment thereof that specifically binds ANGPTL3.

The present invention provides methods for treating patients suffering from hyperlipidaemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to angiopoietin-like protein 8 (ANGPTL8) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3). The combination of an anti-ANGPTL8 antibody with an anti-ANGPTL3 antibody is useful in treating diseases such as hypercholesterolemia, including familial hypercholesterolemia (FH), both heFH and hoFH, as well as hyperlipidaemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

Methods and kits for propagating hematopoietic stem cells are provided. The methods comprise culturing cells in medium comprising one or more angiopoietin-like proteins, under conditions sufficient for expansion of HSCs. Angiopoietin-like proteins include angiopoietin-like protein 2, angiopoietin-like protein 3, angiopoietin-like protein 4, angiopoietin-like protein 5, angiopoietin-like protein 7, and microfibrillar-associated glycoprotein (Mfap4). Methods for identifying hematopoietic stem cells are provided and isolated hematopoietic stem cells are also provided.

The invention relates to ANGPTL4 as a marker of liver cancer metastasis by serological detection and an application thereof. Specifically, the invention provides an application of angiopoietin-like protein 4(ANGPTL4 protein) in (a) the preparation of a diagnostic reagent or kit for the detection of liver cancer metastasis and (b) the preparation of a diagnostic reagent or kit for serological detection of liver cancer. The invention also provides a related detection kit. The invention also provides a method for inhibiting hepatoma cell metastasis by the use of an antagonist of the ANGPTL 4 protein.

Provided are a siRNA for inhibiting the expression of an angiopoietin-like protein 3 (ANGPTL3) gene, and a pharmaceutical composition and a conjugate comprising the siRNA; wherein each nucleotide in the siRNA is independently a modified or unmodified nucleotide, and the siRNA comprises a sense strand and an antisense strand; the sense strand comprises a nucleotide sequence A, the nucleotide sequence A having the same length as the nucleotide sequence as represented by SEQ ID NO:1 with no more than 3 nucleotide differences; the antisense strand comprises a nucleotide sequence B, the nucleotide sequence B having the same length as the nucleotide sequence as represented by SEQ ID NO:2 with no more than 3 nucleotide differences.

The present invention provides methods for treating patients suffering from hypercholesterolemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3). The combination of an anti-PCSK9 antibody with an anti-ANGPTL3 antibody is useful in treating diseases such as hypercholesterolemia, including familial hypercholesterolemia (FH), both heFH and hoFH, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

The present disclosure provides binding agents, such as antibodies, that specifically bind Angiopoietin-like protein 8 (ANGPTL8), including human ANGPTL8, and methods of their use.

The invention provides a method for prokaryotic expression of recombinant chicken ANGPTL4 protein, comprising the following steps: (1) artificially synthesizing a gene sequence of recombinant chickenANGPTL4, and constructing the gene sequence into a prokaryotic expression vector to construct a recombinant prokaryotic expression vector; (2) transforming Escherichia coli E.coli competent cells by using the recombinant prokaryotic expression vector, and screening positive bacterial colonies; (3) carrying out amplification culture on the recombinant positive plasmid single colony, and adding an inducer to carry out inducible expression; (4) carrying out inclusion body renaturation by adopting a dilution renaturation method; and (5) purifying the inclusion body renaturation protein. By constructing a prokaryotic expression vector of the recombinant chicken ANGPTL4, the recombinant chicken ANGPTL4 is efficiently expressed in escherichia coli, the expressed recombinant protein exists in theform of an inclusion body, correct folding of the protein is promoted through inclusion body renaturation and renaturation protein purification, and the expression quantity of the fusion protein is increased. The recombinant chicken ANGPTL4 protein provided by the invention can adjust fat metabolism of broiler chickens, and provides a good test material for development of chicken ANGPTL4 functionresearches in the future.

The present disclosure provides binding agents, such as antibodies, that specifically bind Angiopoietin-like protein 8 (ANGPTL8), including human ANGPTL8, and methods of their use.

The invention relates to an ANGPTL4 as a marker of hypoxia detection and an application thereof. Specifically, the invention provides the use of angiopoietin-like protein 4 (ANGPTL4 protein) in the preparation of a diagnostic reagent or a kit of hypoxia detection. The invention further provides a corresponding hypoxia detection kit.

The present invention provides methods for treating patients suffering from hypercholesterolemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3). The combination of an anti-PCSK9 antibody with an anti-ANGPTL3 antibody is useful in treating diseases such as hypercholesterolemia, including familial hypercholesterolemia (FH), both heFH and hoFH, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

The invention discloses an application of angiopoietin-like protein 7 in prognosis evaluation of heart failure. When a serum sample of a heart failure patient is detected by using an enzyme-linked immunosorbent assay method, and the content of the angiopoietin-like protein 7 in the sample is greater than or equal to 869 pg / mL, the patient has a high probability of poor prognosis, i.e., events of 30-day death and 90-day death can occur at a large probability. According to the application, the angiopoietin-like protein 7 is used as a marker for prognosis evaluation of heart failure, and the prognosis condition of the heart failure patient can be judged by detecting the concentration of the ANGPTL7 in serum. Through predicting the prognosis condition of the heart failure patient by utilizingthe marker, the application is simple and easy to implement and precise in result, has a guiding effect on a clinical treatment scheme, has good application advancement and value, and is worthy of vigorous popularization and protection.

Embodiments of the disclosure concern methods and compositions for treatment of a cardiac-related medical condition. In particular embodiments, ANGPTL8 is provided to an individual in need thereof for the treatment or prevention of a cardiac-related medical condition. In certain cases, ANGPTL8 is provided to an individual with cardiomyopathy, such as Adriamycin-induced cardiomyopathy, using ultrasound-targeted microbubble destruction.

The present invention discloses a culture system used for umbilical cord blood hematopoiesis stem cell amplification and application thereof, the culture system includes an AIM-V culture medium, platelet lysate PL, stem cell factor SCF, human FMS-like tyrosine kinase 3 ligand Flt-3L , G-CSF and IL-3, and angiopoietin-likeprotein 3 (ANGPTL3), small molecule compound StemRegenin (SR1) and pyrimidine-indole molecule UM171 are also added. By adding of the appropriate concentration of ANGPTL3, SR1 and UM171 for combination, the number of hematopoiesis stem cell population is greatly increased, the culture system is used for umbilical cord blood hematopoiesis stem cell growth and amplification, to be more important, implantation capacity and hematopoietic system reconstruction capacity after hematopoietic stem cells are transplanted into a receptor are significantly improved, and the culture system opens up new use prospects in clinical amplification of umbilical cord blood stem cells.

The present invention provides methods for treating patients suffering from hyperlipidemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to angiopoietin-like protein 8 (ANGPTL8) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3). The combination of an anti-ANGPTL8 antibody with an anti-ANGPTL3 antibody is useful in treating diseases such as hypercholesterolemia, including familial hypercholesterolemia (FH), both heFH and hoFH, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

The invention discloses a multi-joint detection kit for rapidly detecting liver diseases and a preparation method thereof. The multi-joint detection kit adopts a fluorescence immunochromatographic method; four fluorescence detection cards are prepared from four markers, including angiopoietin-like protein 2 (angptl2), alpha fetoprotein (AFP), serum osteopontin (OPN) and human cartilage glycoprotein (YKL-40), which are used for detecting liver diseases; the four detection cards are arranged and connected together in parallel to form a kit body; every two adjacent detection cards have a sample adding hole; and each detection card is provided with a card reading window. The multi-joint detection kit can detect four different markers of liver diseases at the same time, can comprehensively monitor liver cirrhosis, liver cancer and liver cancer prognosis, and enables early detection of liver diseases to be faster and more precise; and the operation is simple, the detection time is short, four detection results can be obtained only by adding samples twice, and the results can be obtained within 10 minutes after sample adding is completed, so that the multi-joint detection kit is more suitable for primary level application.

The invention relates to a method for regulating expression of vascular cell adhesion molecule-1 in a vascular endothelial cell. Specifically, the invention provides a method for regulating the expression of the vascular cell adhesion molecule-1 (VCAM-1) through an angiopoietin-like protein 4 (ANGPTL4 protein). The invention also provides application of the ANGPTL4 protein in preparing promoters promoting (VCAM-1) expression.

Provided are a siRNA for inhibiting the expression of an angiopoietin-like protein 3 (ANGPTL3) gene, and a pharmaceutical composition and a conjugate comprising the siRNA; wherein each nucleotide in the siRNA is independently a modified or unmodified nucleotide, and the siRNA comprises a sense strand and an antisense strand; the sense strand comprises a nucleotide sequence A, the nucleotide sequence A having the same length as the nucleotide sequence as represented by SEQ ID NO:1 with no more than 3 nucleotide differences; the antisense strand comprises a nucleotide sequence B, the nucleotide sequence B having the same length as the nucleotide sequence as represented by SEQ ID NO:2 with no more than 3 nucleotide differences.

The invention provides application of a substance inhibiting angiopoietin-like protein 8. The application includes application of the substance inhibiting the angiopoietin-like protein 8 in preparation of products for preventing or treating diseases related to hypertension and / or vascular remodeling. The application of the substance inhibiting the angiopoietin-like protein 8 has the advantages that the substance inhibiting the angiopoietin-like protein 8 inhibits endoplasmic reticulum stress pathways of smooth muscle cells and suppresses proliferation and migration of the smooth muscle cells by inhibiting collagen deposition, and further can effectively reduce the blood pressure and the thickness of blood vessel walls, so that hypertension and vascular remodeling are prevented and treatedeffectively; the substance inhibiting the angiopoietin-like protein 8 can effectively improve the therapeutic effect on hypertension and vascular remodeling when being applied to the products for preventing or treating the diseases related to the hypertension and / or vascular remodeling, thereby having a good application prospect.

Angiopoietin-like protein (ANGPTL)3 / 8 fusion proteins are disclosed. Nucleic acid constructs encoding ANGPTL3 / 8 fusion proteins also are disclosed. Methods of making and using the same also are disclosed, especially for generating antibodies against ANGPTL3 and / or ANGPTL8.

The invention relates to a method for regulating expression of vascular cell adhesion molecule-1 in a vascular endothelial cell. Specifically, the invention provides a method for regulating the expression of the vascular cell adhesion molecule-1 (VCAM-1) through an angiopoietin-like protein 4 (ANGPTL4 protein). The invention also provides application of the ANGPTL4 protein in preparing promoters promoting (VCAM-1) expression.

The present application provides the use of a substance for detecting angiopoietin-like protein 8 content. The application includes the application of a substance for detecting the content of angiopoietin-like protein 8 in preparing a product for predicting or assisting in predicting recurrent adverse cardiovascular events after percutaneous coronary intervention. The application of the substance for detecting the content of angiopoietin-like protein 8 provided in this application can be applied to the prediction of adverse cardiovascular events in patients with coronary heart disease after PCI, and the prediction of PCI in patients with coronary heart disease. The risk probability of adverse cardiovascular events occurring later is high and accurate, and it can advance the decision-making time of active clinical intervention before the occurrence of adverse cardiovascular events. value.

The present invention provides methods and compositions for treating or preventing atherosclerosis in a subject. The methods of the present invention comprise administering an inhibitor of angiopoietin-like protein-3 (ANGPTL3) to a subject who has atherosclerosis or is at risk of developing atherosclerosis. In certain embodiments, the ANGPTL3 inhibitor is an antibody or antigen-binding fragment thereof that specifically binds ANGPTL3.

Methods and kits for propagating hematopoietic stem cells are provided. The methods comprise culturing cells in medium comprising one or more angiopoietin-like proteins, under conditions sufficient for expansion of HSCs. Angiopoietin-like proteins include angiopoietin-like protein 2, angiopoietin-like protein 3, angiopoietin-like protein 4, angiopoietin-like protein 5, angiopoietin-like protein 7, and microfibrillar-associated glycoprotein (Mfap4). Methods for identifying hematopoietic stem cells are provided and isolated hematopoietic stem cells are also provided.

The invention relates to ANGPTL4 as a marker of liver cancer metastasis by serological detection and an application thereof. Specifically, the invention provides an application of angiopoietin-like protein 4(ANGPTL4 protein) in (a) the preparation of a diagnostic reagent or kit for the detection of liver cancer metastasis and (b) the preparation of a diagnostic reagent or kit for serological detection of liver cancer. The invention also provides a related detection kit. The invention also provides a method for inhibiting hepatoma cell metastasis by the use of an antagonist of the ANGPTL 4 protein.

The invention discloses an application of angiopoietin-like protein 4 in protecting the barrier function of endothelia and discloses an application of the angiopoietin-like protein 4 in preparing a product for protecting and / or enhancing the shielding function of cells. The application proves that the angiopoietin-like protein 4 has the effect of protecting the shielding function of the endothelia, and can relieve myocardial-ischemia reperfusion injury of diabetes.